Objective: To investigate whether adiponectin receptor genes (AdipoR1 and AdipoR2) expression in human subcutaneous (SAT) and visceral (VAT) adipose tissue in severely obese patients with or without diabetes is related to adiponectin gene (APM1) expression and in vivo metabolic parameters. Design: Cross-sectional, clinical research study. Subjects: Total RNA was extracted from SAT and VAT tissue obtained during surgery from 13 lean controls, 30 obese diabetic patients, 19 obese glucose-intolerant patients and 54 obese subjects with normal glucose tolerance. Measurements: Tissue expression of APM1, AdipoR1 and AdipoR2, tissue concentration of adiponectin (ApN), and metabolic variables. Results: APM1 expression was higher in SAT than VAT (1.0670.76 vs 0.6970.52, Po0.0001) as was AdipoR1 (1.1770.70 vs 0.6670.38, Po0.0001) and AdipoR2 (7.0276.19 vs 0.7570.64, Po0.0001). In SAT, APM1 and AdipoR1 expression tended to be lower -by 0.3870.22 and 0.3570.22, respectively -and AdipoR2 expression was markedly depressed -by 4.8271.93 -in association with obesity, whereas presence of diabetes had no additional effect. In VAT, APM1 and AdipoR1 expressions were also reduced -by 0.3670.16 and 0.3070.11, respectively -in association with obesity. Within both SAT and VAT, expression levels of APM1, AdipoR1 and AdipoR2 were all positively interrelated. Tissue ApN concentrations in SAT were similar across groups, whereas ApN levels in VAT were substantially lower in association with obesity (by an average of 63712 ng/mg total protein, Po0.0001). In multivariate models adjusting for sex, age and obesity, serum triglyceride concentrations were reciprocally related to APM1 (r ¼ À0.27, Po0.02), AdipoR1 (r ¼ À0.37, Po0.002 and AdipoR2 expression (r ¼ À0.37, Po0.002) in VAT. Likewise, plasma insulin concentrations were inversely related only to APM1 in VAT (r ¼ À0.25, Po0.03). Conclusions: Severe obesity is associated with suppressed expression of both ApN and its receptors in both SAT and VAT, the expression levels in VAT are specifically linked with hyperinsulinemia and dyslipidemia.
Introduction
Obesity, especially central obesity, is part of a cluster of abnormalities -including insulin resistance, type 2 diabetes (DM2), hypertension and dyslipidemia -that enhances the risk of cardiovascular disease. 1 Several molecules produced by adipose tissue, known as adipocytokines, circulate in increased concentration in several metabolic conditions. [2] [3] [4] [5] [6] Adiponectin (ApN), which is also exclusively produced by adipocytes, [7] [8] [9] is associated with improved insulin sensitivity through its stimulatory effect on fatty acid oxidation 10, 11 and inhibitory action on hepatic glucose production. 12, 13 Plasma ApN levels have been found to be significantly reduced in subjects with obesity, insulin resistance or DM2; [14] [15] [16] [17] the mechanisms of this reduction are incompletely understood. A reduction in adiponectin gene (APM1) expression and secretion in adipose tissue from obese and diabetic subjects has been reported in some, 7, [18] [19] [20] [21] [22] but not all studies. 23 Moreover, the role of omental vs subcutaneous adipose tissue (SAT) in ApN release and the relationship between the protein and its receptors in adipose tissue have not been fully investigated. Two adiponectin receptors (AdipoR1 and AdipoR2), G protein-coupled domains, have been identified and their genes (AdipoR1 and AdipoR2) have been recently cloned. 24 AdipoR1 appears to have a high affinity for globular and a low affinity for full-length ApN, whereas AdipoR2 has intermediate affinity for both ApN isoforms. AdipoR1 has been reported to be more expressed in skeletal muscle, AdipoR2 in the liver. 24 Both receptors are reputed to mediate ApN effects on adenosine monophosphate kinase (AMPK), peroxisome proliferator-activated receptor-a ligands activities, fatty oxidation and glucose uptake. 15, [25] [26] [27] Recently, Fasshauer et al. 28 have demonstrated the presence of both receptors in an adipocyte cell line, and Rasmussen et al. 29 have found that AdipoR1 expression is reduced in adipose tissue of obese subjects. The present study was undertaken to assess the separate role of obesity and DM2 in the expression of the APM1 and both its receptors in visceral adipose tissue (VAT) and SAT and to explore the relationships between these expression levels and metabolic traits.
Subjects and methods

Subjects and study design
The study involved 103 severely obese subjects undergoing bariatric surgery; 13 non-obese subjects undergoing elective abdominal surgery (cholecystectomy) served as the control group. All subjects gave informed, written consent, and the protocol was approved by the local Ethical Committee. The obese subjects were subgrouped according to their glucose tolerance status (as determined by a standard 75-g oral glucose tolerance test (OGTT) or a previous diagnosis of DM2): 54 subjects had normal glucose tolerance status (Obese-NGT), 19 had impaired glucose tolerance (Obese-IGT) and 30 had DM2 (Obese-DM2). All patients were asked to attend our Unit for the metabolic study 2 weeks before surgery. All subjects were instructed not to exercise for 48 h before the metabolic study or surgery. For the metabolic study, all subjects were examined in the morning after an overnight (12-14 h) fast. Peripheral blood samples were obtained for determination of lipid profile, glucose, insulin and ApN concentrations. Then a 75-g OGTT was performed, with sampling every 15 min within the first hour and every 30 min for the following 2 h, for measurement of plasma glucose and insulin. IGT and diabetes were classified according to the American diabetes association (ADA) criteria. 30 Thus, IGT was classified as a fasting plasma glucose concentrations o7.0 mmol/l and 2-h plasma glucose between 7.8 and 11.1 mmol/l. Diabetes was classified as a fasting glucose X7.0 mmol/l or 2-h glucose 411.1 mmol/l. Diabetic subjects who were not taking insulin were considered to have DM2; insulin-taking diabetic subjects whose age of onset was X40 years or whose body mass index (BMI) was 430 kg/m 2 were also considered to have DM2. The remaining insulin-taking diabetic subjects were considered to have type 1 diabetes or to be unclassifiable, and were excluded from the study. Anthropometric measurements, height, weight, waist and hip circumferences, and systolic and diastolic blood pressure, were measured as described elsewhere. 31 Adipose tissue biopsies SAT and VAT fat depots (1-2 g) were collected during abdominal surgery in RNA-Later and stored at À201C for total RNA extraction. In a subgroup of 20 Obese-NGT, six Obese-IGT, 11 Obese-DM2 and 10 controls, an additional 300-mg adipose tissue specimen from both SAT and VAT was collected and immediately transported in sterile containers to the laboratory (30 min after removal).
Total RNA isolation and cDNA preparation The adipose tissue was cut into pieces of 600 mg, and after removing RNA-Later, total RNA was isolated using a mixed protocol: Trizol and RNeasy Midi Kit (Qiagen, Hilden, Germany) in order to obtain a larger amount of purified RNA. RNA was quantified by measuring absorbance at 260 and 280 nm. RNA integrity was then checked by visual inspection of the two ribosomal RNAs, 18S and 28S, on 1% agarose gel. Average yields of total RNA were 2071 mg/g of adipose tissue. Isolated RNA was stored at À801C until quantification of the target mRNAs. For first-strand cDNA synthesis, 1 mg total RNA was reverse-transcribed in a 20 ml volume using random hexamers as primers, according to the manufacturer's instructions (First strand cDNA Synthesis Kit for RT-PCR, AMV, Roche, Indianapolis, IN, USA).
Relative quantification of APM1, AdipoR1, AdipoR2 gene expression Relative quantification of the mRNAs was performed by realtime PCR using a Light-Cycler instrument (Roche Diagnostics, Adiponectin receptors expression in fat depots M Nannipieri et al Mannheim, Germany). Gene-specific primers for the target genes (APM1: forward 5 0 -TGGTGAGAAGGGTGAGAA-3 0 and reverse 5 0 -AGATCTTGGTAAAGCGAATG-3 0 , 221 bp; AdipoR1:
0 , 97 bp) and the reference gene (hypoxantinephosphorybosyl-transferase, HPRT: forward 5 0 -TGCTGACCT GCTGGATTACAT-3 0 , reverse 5 0 TTGCGACCTTG-ACCATCTTT-3 0 , 260 bp) were designed in our laboratory. HPRT mRNA was used for sample normalization. cDNA (1 ml) was brought to a final volume of 20 ml in a glass capillary containing 1 Â LightCycler-FastStar DNA Master SYBR Green I mix (Roche Diagnostics), 4.5 mM MgCl 2 and 0.3 mM of primers (Proligo, Paris, France) for APM1, AdipoR1 and AdipoR2 and 0.5 mM for HPRT. PCR was performed with 10 min of initial denaturation and then 40 cycles with 10 s at 951C (denaturation), 7 s at 581C (annealing) and 13 s at 721C (extension). The last cycle at 401C for 15 s. Fluorescent data were acquired at the end of each extension phase. After amplification, a melting curve analysis from 65 to 951C with heating rate of 0.11C/s with a continuous fluorescence acquisition was constructed. To construct standard curves for each gene, total RNA from six control subjects (SAT and VAT) were pooled. In brief, after RNA reverse transcription of pool sample, the cDNA was diluted into threefold serial dilution (1:3-1:27) and both genes (target and reference) were amplified in triplicate. The standard curve was used to assess PCR efficiency. Standard curves were accepted only if the slope for each gene was around -3 with an r value 40.98. Each cDNA was quantified in triplicate. For the relative quantification of samples, the 'Light Cycler Relative Quantification Software' was utilized. Results were expressed as the target/reference ratio of each sample, normalized by the target/ reference ratio of the calibrator. The calibrator used for each quantification was the sample with a dilution of 10 À3 utilized in the standard curve. In the present data, the coefficient of variation in measurements for the target gene in each sample ranged 0-10%. We used HPRT as the reference gene because its expression was found to be relatively stable in different adipose tissue depots and showed no systematic differences between cases and controls. The mean C t (7s.d.) of HPRT was 25.7271.42 in obese subjects compared to 25.6371.95 in the control group for SAT, and 25.1971.24 in obese subjects compared to 25.4771.73 in the control group for VAT.
Adipocyte isolation and measurement of intracellular ApN concentrations Mature adipocytes were isolated as described by Grohmann et al. 32 The adipose tissue was washed three times in Hank's balanced salt solution, cut into 1-mm 3 pieces and digested with 3 ml of 4 mg/ml type II collagenase in Hank's balanced salt solution for 60 min at 371C. Fragments of tissue still remaining after this treatment were removed with forceps. The mature adipocytes were separated from the stromal fraction by centrifugation at 90 g for 3 min and were carefully removed to a sterile Eppendorf containing 500 ml of lysis buffer (10 mM Tris-Cl, 50 mM NaCl, 5 mM ethylenediaminetetraacetic acid, 15 mM sodium pyrophosphate, 50 mM sodium fluoride, 100 mM sodium orthovanadate and 1% Triton X-100 with freshly added 1% phenylmethylsulfonyl fluoride at the time of use). Cells were then lysed via repeated passaging through a 21-gauge needle and the fat cake at the top of the sample was carefully removed. Then the samples were frozen at À201C. Samples were processed in batch, and ApN concentrations were determined using a standard ELISA assay; adipose tissue ApN concentrations were corrected for mg of total protein. 
Statistical analysis
Results
The clinical characteristics of the study population are reported in Table 1 . The obese groups generally had similar clinical phenotypes, but blood pressure, serum triglycerides, Adiponectin receptors expression in fat depots M Nannipieri et al fasting and 2-h plasma glucose levels and fasting plasma insulin concentrations were higher in patients with DM2 than in obese NGT patients, while IGT patients showed intermediate values.
In the whole data set, APM1 expression was higher in SAT than VAT (1.0670.76 vs 0.6970.52, Po0.0001) as was AdipoR1 expression (1.1770.70 vs 0.6670.38, Po0.0001). For AdipoR2 expression, levels were B10-fold higher in SAT than VAT (7.0276.19 vs 0.7570.64, Po0.0001). These differences were maintained across study groups (Table 2) .
In SAT, APM1 and AdipoR1 expression tended to be lower -by 0.3870.22 and 0.3570.22, respectivelyand AdipoR2 expression was markedly depressed -by 4.8271.93 -in association with obesity, whereas presence of diabetes had no additional effect. Within SAT, expression levels of APM1, AdipoR1 and AdipoR2 were all positively interrelated.
In VAT, APM1 and AdipoR1 expression were significantly lower -by 0.3670.16 and 0.3070.11, respectively -in association with obesity, whereas AdipoR2 expression tended to be reduced but the difference did not reach statistical significance. As was the case for SAT, expression levels were all positively interrelated and there was no independent influence of diabetes on them.
Plasma ApN concentrations were significantly lower in association with obesity (by 2.471.1 mg/l on average, Po0.03), with no independent effect of diabetes. In the whole data set, APM1 expression in SAT and VAT, AdipoR1 expression in SAT and AdipoR2 expression in VAT were each reciprocally related to BMI (with rho values of 0.19-0.21, all Pp0.05). A positive correlation was also found between plasma ApN and APM1 expression in VAT (rho ¼ 0.32, Po0.001), but not with receptors expression in VAT or APM1 expression in SAT.
ApN concentrations in mature adipocytes of SAT were similar across groups, whereas ApN levels in VAT were substantially lower in association with obesity (by an average of 63712 ng/mg total protein, Po0.0001) ( Table 2) . In a multivariate model adjusting for sex, age, and obesity, plasma insulin concentrations were inversely related only to APM1 in VAT (sd.r ¼ À0.25, Po0.03).
Discussion
The major findings of the present study are that: (1) both APM1 and its receptors, especially AdipoR2, are expressed at higher levels in SAT than in VAT; (2) circulating ApN levels are related to APM1 but not receptor expression; (3) expression of APM1 and both receptors is reduced in association with obesity but not diabetes and (4) adipocyte ApN concentrations are reduced in VAT of obese individuals. These findings are generally compatible with the notion that ApN is a link between visceral fat accumulation and insulin resistance, [33] [34] [35] but require specification.
Firstly, there is some disagreement about the absolute level of expression of APM1 and its receptors in different fat depots. Thus, Tan et al. 36 could not find any correlation between APM1 expression and receptor expression in subcutaneous abdominal fat of patients with DM2. Rasmussen et al. 29 on the other hand, reported higher expression of AdipoR1 than AdipoR2 in both SAT and VAT in a group of obese non-diabetic women. In our large group of subjects, we found that AdipoR2 is the dominant receptor expressed in SAT but not in VAT regardless of gender and clinical condition (obesity or diabetes). Also, in our hands, the expression levels of APM1 and its receptors were correlated with each other in both adipose depots. The reasons for the discrepancy in the relative abundance of AdipoR1 and AdipoR2 in different tissues remain unclear. Upon re-assaying a representative sample of our tissue specimens with the use of a different reporter gene (GADPH), we found a similar pattern of results (data not shown). Secondly, in our study population, circulating ApN levels were weakly related to gene expression in VAT only. A lack of association between serum ApN levels and SAT APM1 expression has been observed previously. 10, 34 Hoffstedt et al. 37 have reported that ApN release by SAT is reduced in obese women when expressed per unit of fat tissue weight, but found a (weak) correlation between secretion and circulating level of the adipokine only in women with high insulin sensitivity. In general, it is difficult to extrapolate APM1 expression or tissue secretion rates to circulating levels because (1) ApN has a fast plasma clearance rate, (2) at the Our results, while confirming lower expression and plasma concentrations in association with obesity, do not show an independent effect of hyperglycemia, in agreement with Koistinen et al. 40 On the other hand, our diabetic subjects were all severely obese, so that expression and circulating levels may have bottomed out (a 'floor effect'). Therefore, we cannot completely rule out that hyperglycemia in non-obese (or less obese) subjects may be associated with suppressed ApN. Both AdipoR1 and AdipoR2 were found to be less expressed in the adipose tissue of our obese subjects, in SAT as well as VAT. This finding agrees with recent results by Rasmussen et al. 29 Importantly, we found a reciprocal association between the expression of APM1 and its receptors in VAT and serum triglyceride levels that was independent of gender, age and degree of obesity. This result clearly suggests that the biology of ApN in VAT is relevant to the metabolic status of the subject. Thus, as the adipose mass expands, ApN and its receptors decrease in all adipose tissue depots, possibly as a result of changes in cellular phenotype (from small, insulin sensitive adipocytes to large, insulin-resistant cells). In line with the notion that insulin -or insulin resistance -may directly influence APM1 receptors mRNA in adipose and muscle tissue, 28,41-44 we observed a negative association between plasma insulin concentrations and APM1 expression. Whether the two receptors mediate different physiological actions in SAT and VAT or whether the relative abundance of the receptors in VAT vs SAT is a factor in the physiological actions of ApN are questions that require further investigation. In summary, this study demonstrates that APM1 expression is directly related to the expression of its receptors in abdominal adipose tissue, and that lower levels of APM1 receptors mRNA are found in VAT than SAT. Furthermore, we found that obesity -but not diabetes -is associated with lower expression of APM1 and its receptors in both abdominal fat depots, but that only VAT gene expression is related to metabolic parameters. Although our findings are compatible with the suggestion that the ApN system in visceral fat tissue is involved in the pathogenesis of obesity and insulin resistance, further studies are necessary to determine whether changes in gene expression translate into changes in protein levels and biological function.
